Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2025
(5 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(7 years from now) | |
US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(7 years from now) | |
US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
Dosage: SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(9 years from now) | |
US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-844) | Sep 25, 2023 |
New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(a month from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(a month from now) | |
US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) | |
US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9662335 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(2 years from now) | |
US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(3 years from now) | |
US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(2 years from now) | |
US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(2 years from now) | |
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(2 years from now) | |
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(2 years from now) | |
US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) | |
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
New Indication(I-699) | Dec 04, 2017 |
Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
New Indication(I-799) | May 24, 2022 |
New Indication(I-872) | Sep 22, 2024 |
M(M-285) | Dec 19, 2025 |
Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(7 years from now) | |
US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(7 years from now) | |
US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(7 years from now) | |
US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8293752 | DAY ONE BIOPHARMS | Compounds useful as Raf kinase inhibitors |
Aug, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10426782 | DAY ONE BIOPHARMS | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
Jun, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 23, 2029 |
Orphan Drug Exclusivity(ODE-478) | Apr 23, 2031 |
Drugs and Companies using TOVORAFENIB ingredient
NCE-1 date: 23 April, 2028
Market Authorisation Date: 23 April, 2024
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Mar, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(2 years from now) | |
US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) | |
US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(9 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(1 year, 22 days ago) | |
US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 11 months from now) | |
US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(4 years from now) | |
US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(1 year, 22 days ago) | |
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(6 months ago) | |
US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 11 months from now) | |
US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(1 year, 11 months from now) | |
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(2 years from now) | |
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(2 years from now) | |
US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(3 years from now) | |
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(3 years from now) | |
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(4 years from now) | |
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
New Indication(I-627) | Jun 17, 2014 |
Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
New Dosing Schedule(D-170) | Dec 22, 2020 |
New Patient Population(NPP) | Mar 22, 2021 |
Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 17 June, 2010
Treatment: A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(5 years from now) | |
US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(13 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(13 years from now) | |
US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(13 years from now) | |
US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8598210 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
USRE47437 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(3 years from now) | |
US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(3 years from now) | |
US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(10 years from now) | |
US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(10 years from now) | |
US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8940773 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(3 years from now) | |
US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(9 years from now) | |
US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(10 years from now) | |
US11844756 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(11 years from now) | |
US11324734 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(11 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9796741 | ALEXION PHARMS INC | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
Dosage: TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6753445 | NABRIVA | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(3 years ago) | |
US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(3 years from now) | |
US8071643 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(4 years from now) | |
US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
Dosage: SOLUTION; TABLET
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10953003 | X4 PHARMS | Methods for treating cancer |
Dec, 2036
(12 years from now) | |
US11219621 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(12 years from now) | |
US10610527 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(12 years from now) | |
US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(14 years from now) | |
US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome
Dosage: CAPSULE
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 10 months from now) | |
US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 10 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(6 years from now) | |
US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(6 years from now) | |
US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(7 years from now) | |
US9289442 | LNHC | Topical compositions |
Jul, 2032
(7 years from now) | |
US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(7 years from now) | |
US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(10 years from now) | |
US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(10 years from now) | |
US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel; Method of application of topical pharmaceutical composition to treat dermatological condition; Method of...
Dosage: GEL